Company intelligence / Profile preview
MEBO Group
- Ownership
- Private
- Employees
- ~224
- Development stage
- Other
Overview
MEBO’s core product—Moist Exposed Burn Ointment—has been used to treat millions of patients worldwide for burns and wounds. The company claims broad clinical adoption across 110+ countries. Its skin regeneration drug is preparing for Phase III trials with the FDA in the US. Other marketed products include creams, wound dressings, GI capsules, and nutritional supplements based on regenerative medicine principles
- Therapeutic areas
- DermatologyGastroenterologyOther
- Modalities
- Small molecule (botanical drug products)Biologic (regenerative medical devices and tissue engineering products)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MEBO Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEBO Group.